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Abstract
Background: Although cigarette smoking has been associated with carotid intima-media thickness (CIMT) the
mechanisms are yet not completely known. Lysophosphatidylcholine (lysoPC), a main product of lipoprotein-
associated phospholipase A2 (Lp-PLA2) activity, appears to be a major determinant of the pro-atherogenic properties
of oxidized LDL (oxLDL) and to induce proteoglycan synthesis, a main player in intimal thickening. In this study we
assessed whether cigarette smoking-induced oxidative stress may influence plasma Lp-PLA2 and lysoPC and Lp-
PLA2 expression in peripheral blood mononuclear cells (PBMC), as well as the relationship between lysoPC and
CIMT.
Methods/Results: 45 healthy smokers and 45 age and sex-matched subjects participated in this study. Smokers,
compared to non-smokers, showed increased plasma concentrations of oxLDL, Lp-PLA2 and lysoPC together with
up-regulation of Lp-PLA2 (mRNA and protein) expression in PBMC (P<0.001). Plasma Lp-PLA2 positively correlated
with both lysoPC (r=0.639, P<0.001) and PBMC mRNA Lp-PLA2 (r=0.484, P<0.001) in all subjects. Moreover CIMT
that was higher in smokers (P<0.001), positively correlated with lysoPC (r=0.55, P<0.001). Then in in vitro study we
demonstrated that both oxLDL (at concentrations similar to those found in smoker’s serum) and oxidized
phospholipids contained in oxLDL, were able to up-regulate mRNA Lp-PLA2 in PBMC. This effect was likely due, at
least in part, to the enrichment in oxidized phospholipids found in PBMC after exposure to oxLDL. Our results also
showed that in human aortic smooth muscle cells lysoPC, at concentrations similar to those found in smokers,
increased the expression of biglycan and versican, two main proteoglycans.
Conclusions: In smokers a further effect of raised oxidative stress is the up-regulation of Lp-PLA2 expression in
PBMC with subsequent increase of plasma Lp-PLA2 and lysoPC. Moreover the correlation between lysoPC and
CIMT together with the finding that lysoPC up-regulates proteoglycan synthesis suggests that lysoPC may be a link
between smoking and intimal thickening.
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Introduction
Cigarette smoking is a major risk factor for atherosclerotic
vascular disease and it is an important factor contributing to
premature vascular aging [1-3]. Emerging evidence
demonstrates that oxidative stress and activation of
inflammatory pathways contribute to many of the
pathophysiologic manifestations of cigarette smoking [2-6].
Free radicals from cigarette smoking also cause peroxidation of
the polyunsaturated fatty acids of cell membranes that amplify
oxidative stress during smoking [5,6].
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an
emerging and independent risk factor for coronary and carotid
artery disease [7], that in animal studies has been shown to be
involved in the causal pathway of the intimal oxidative-
inflammatory cascade typical of atherogenesis [8]. In particular,
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a positive association between Lp-PLA2 activity and circulating
oxidized low-density lipoprotein (oxLDL) has been shown in a
hypercholesterolemic swine model of atherosclerosis [9].
Moreover, it has been recently reported that oxLDL can up-
regulate the expression of Lp-PLA2 in THP1 monocyte-like
cells and in human monocyte-derived macrophages [10]. Lp-
PLA2 that is secreted predominantly by inflammatory cells,
circulates in plasma mainly bound to LDL [8]. The oxidation of
LDL within the arterial wall, a key factor in atherogenesis,
yields oxidized phospholipids that are the substrate for Lp-
PLA2 reaction, producing lysophosphatidylcholine (lysoPC)
and oxidized free fatty acids both of which exhibit several pro-
atherogenic effects [8,11]. In vitro observations have
demonstrated that lysoPC is a major determinant of the pro-
atherogenic properties of oxLDL and activates the redox-
sensitive inflammatory pathways by increasing the recruitment
of leukocytes and by inducing endothelial dysfunction and
apoptosis of endothelial and vascular smooth muscle cells
(SMCs) [8,11].
Ultrasound-measured carotid intima-media thickness (CIMT)
represents a measure of early alterations of the arterial walls,
that has been widely used as a markers of subclinical
atherosclerosis and a predictor of future cardiovascular disease
events [10,12,13]. In this context, however, the accuracy of
CIMT as a marker of atherosclerosis is mired by the fact that
main predictors of medial hypertrophy or intimal thickening are
age and hypertension [14]. Moreover, in clinical cardiology,
smokers often present (at a younger age) myocardial infarction
without extensive visible coronary atherosclerosis [2,15].
Although epidemiological studies have consistently shown that
cigarette smoking is associated with higher CIMT [16,17], the
mechanisms are likely multifaceted and not yet fully
understood. It has been previously suggested that cigarette
smoking has a specific fibrogenic effect which causes intimal
thickening [3,4]. “Secretory” vascular SMCs, the major cellular
component of the neointima, secrete predominantly the small
chondroitin sulfate/dermatan sulfate proteoglycans biglycan
and decorin, as well as versican and the heparan sulfate
proteoglycans perlecan [18,19]. The retention of LDL via their
interaction with biglycan and versican at sites of intimal
thickening is believed to be a key step in early atherogenesis
[20-22]. Interestingly, oxLDL was demonstrated to up-regulate
biglycan synthesis in vascular SMCs, resulting in enhanced
lipoprotein-proteoglycans binding [23]. Moreover, among the
several bioactive lipids contained in oxLDL, only lysoPC was
shown to increase biglycan synthesis [24], through reactive
oxygen species formation [25].
Then, since in vitro studies have suggested that oxLDL
increase Lp-PLA2 expression and that lysoPC may have a role
in intimal expansion [24], this study aimed to assess whether
cigarette smoking-induced oxidative stress affects Lp-PLA2
expression in peripheral blood mononuclear cells (PBMC) and
hence Lp-PLA2 and lysoPC plasma concentrations, as well as
the relationship between lysoPC and CIMT in otherwise healthy
smokers.
Methods
Ethics statement
The study was approved by the Ethical Committee of the
University of Verona and all participants provided written
consent prior to commencing the study.
Study Population
Ninety (48 males and 42 females) healthy subjects, 23–48
years of age (mean 35.8±6.2 years) were enrolled in the study.
None of the participants had a history of hypertension,
hypercholesterolemia or diabetes mellitus and no medications
were being taken. Of the 90 subjects, 45 were active cigarette
smokers with a mean number of 24.5±8.0 cigarettes/day, a
mean duration of smoking of 16.5±4.2 years, a mean
cumulative cigarette consumption of 17.7±5.2 packs/years and
were thus assigned to the smoking group. The remaining 45
subjects did not have a history of cigarette smoking and were
assigned to the non-smoking group.
CIMT measurement
CIMT is evaluated as distance between the leading edge of
the lumen-intima interface and the leading edge of the media-
adventitia interface [26]. The same investigator, unaware of the
characteristics of the subjects, performed non-invasive
measurements of CIMT using a high-resolution B-mode
ultrasound (Envisor, Philips) equipped with a 7.5-to 12-MHz
linear array transducer imager. For all subjects, CIMT was
measured in the far wall of the common carotid artery (within 1
cm proximal to the carotid bulb), at the bulb and the origin of
the internal carotid artery of both sides [26]. On each arterial
site, mean CIMT values (as averaged across the entire
distance) and maximal CIMT values were recorded using
Carotid Studio, a validated real-time automatic technique for
CIMT measurement [27]. These 6 combined mean and
maximal CIMT far-wall measurements from left and right side
were averaged.
Blood samples and PBMC isolation
Venous blood samples were obtained from each subject
after 12 hours fasting. Multiple aliquots of plasma were added
with antioxidant 2,6-di-tert-butyl-4-methylphenol 10 mmol/l
(Sigma) to inhibit lipid peroxidation and stored at -80° C. PBMC
were isolated as previously described [28]. Briefly, whole blood
was layered onto a sterile aqueous medium containing ficoll
and sodium diatrizoate at a predetermined density of 1.007
g/ml at 25° C. Gentle centrifugation at room temperature
resulted in the separation of PBMC at the blood/ficoll interface,
with the other white and red blood cells passing through the
interface. Total cholesterol, high density lipoprotein (HDL)
cholesterol, LDL cholesterol, triglycerides and glucose were
measured with standard methods.
Measurement of oxLDL, Lp-PLA2 and lysoPC in plasma
of non-smokers and smokers
Plasma circulating oxLDL, collected from whole blood into
Vacutainer tubes containing ethylenediamine tetraacetic acid (1
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mg/ml) was measured with the enzyme-linked immunosorbent
assay Mercodia oxidized-LDL enzyme-linked sandwich
immunosorbent assay kit (Mercodia AB, Uppsala, Sweden), in
which the wells of the microtiter plates are coated with the
capture antibody mAb-4E6 [29]. Cu2+-modified LDL ranging
from 50 to 500 ng/ml was used as a standard solution. Lp-
PLA2 mass was measured using the PLAC test (diaDexus, Inc,
San Francisco, California), a microplate-based enzyme
immunoassay, based on the principle of an enzyme-linked
sandwich immunosorbent assay using 2 highly specific
monoclonal antibodies.
LysoPC 16:0 (1-palmitoyl-2-hydroxy-sn-glycero-3-
phosphocholine) in plasma was measured on an Agilent mass
spectrometer equipped with electrospray ionization ion source.
Experiments were performed with a high-performance liquid
chromatography-mass spectrometry system (HP1100 ion-trap,
Agilent technologies, Waldbronn, Germany); column was a C8
4,6x250 mm (Waters Spherisorb); quantification of the
chromatograms peak areas was performed by single ion
monitoring scan resolution.
LDL isolation and oxidation
LDL was isolated from whole blood of healthy volunteers
after 12 h of fasting by sequential flotation in NaBr solution
containing 1 mg/ml ethylenediamine tetraacetic acid (density
1.019–1.063 g/ml). Immediately before the oxidation
incubations, LDL was separated from ethylenediamine
tetraacetic acid and from diffusible low molecular mass
compounds by gel filtration on PD-10 Sephadex G-25M gel in
10 mmol/l phosphate-buffered saline. Cu2+-modified LDL (1.7
mg of LDL protein/ml) was prepared by exposure of LDL to 5
µmol/l CuSO4 for 18 h at 37° C, as described previously [30].
The extent of LDL oxidation procedure was determined by
evaluating the level of thiobarbituric acid-reactive substances,
as reported [30].
Cell culture
PBMC (3x105/ml, 200 µl/well) from healthy donors were
cultured in RPMI 1640 with L-glutamine (GIBCO), as described
[5].
Human aortic SMCs were purchased from Gibco Cascade
Biologics and cultured in medium 231 according to the
manufacturing instructions: in brief, human aortic SMCs were
plated in 12-well tissue culture plates at a density of 2.0x104
cells/well and were maintained in SMCs growth medium
containing 5% foetal bovine serum, 50 mg/ml gentamicin, and
50 ng/ml amphotericin B at 37° C, 5% CO2/95% air, until
confluence. Because it has been already demonstrated that
proteoglycans synthesis increases significantly in proliferating
cells in comparison with quiescent cells [31], cultures were then
switched to DMEM supplemented with 20% foetal bovine
serum and antibiotics to obtain proliferating cells, or DMEM
containing 1% foetal bovine serum and antibiotics to obtain
quiescent cells, for 3 days.
Preparation of oxidized products of the phospholipid 1-
palmitoyl-2-arachidonyl-sn-glycero-3-
phosphorylcholine (oxPAPC)
PAPC was oxidized by air exposure for 48 hours and the
composition of oxPAPC was analyzed as previously described
[29]. 75 mg of oxPAPC yelded about 0.6–0.7 mg/mL (1.01–
1.17 mmol/L) of 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-
phosphorylcholine (POVPC) and about 0.38–0.45 mg/mL
(0.62–0.74 mmol/L) of 1-palmitoyl-2-glutaroyl-sn-glycero-3-
phosphorylcholine (PGPC). The lipids were extracted with
chloroform and re-suspended in methanol before addition to
the PBMC.
Effect of increasing concentrations of native LDL,
oxLDL, oxPAPC and of lysoPC on mRNA Lp-PLA2
expression in PBMC
PBMC were incubated with increasing concentrations of
native LDL (nLDL) (as control), oxLDL, oxPAPC (0-100 µg/ml)
and of lysoPC (0-50 µmol/l) in RPMI containing 0.2% foetal
bovine serum for 6 hours at 37° C. Standard lysoPC (16:0) was
purchased from Avanti Polar Lipids.
Quantification of POVPC, PGPC and lysoPC in PBMC
after incubation with nLDL or oxLDL
Oxidized products in PBMC were measured on an Agilent
mass spectrometer equipped with an electrospray source as
previously described [32,33]. Among the different oxPAPC,
POVPC and PGPC were taken into consideration because they
have been previously identified as the most bioactive
components [6]. For the experiments, PBMC were incubated
with nLDL or oxLDL (100 µg/ml) for 18 hours at 37° C.
Flow injection experiments were performed by a high-
performance liquid chromatography system as previously
described [29]. Quantification of the peak areas was performed
by single ion monitoring in the elution time range of 10–20 min
using appropriate software. Authentic PAPC, POVPC (593.4
m/z) and PGPC (609.4 m/z) were obtained from Avanti Polar
Lipids, Inc. (Alabaster, AL) [32].
Effect of increasing concentrations of lysoPC on
versican and biglycan (mRNA and protein) expression
in human aortic SMCs
Before the experiments, the medium was changed and both
quiescent and proliferating human aortic SMCs were incubated
without and with increasing concentrations (10-50 µM) of
lysoPC in DMEM containing 0.2% foetal bovine serum for 24
hours at 37° C.
RNA isolation and quantitative real-time PCR
Total RNA was isolated with QIAzol Lysis reagent and
RNEasy Mini Kit (Qiagen, Hilden, Germany). The concentration
and quality of RNA were evaluated using the RNA 6000 Nano
LabChip Kit (Agilent 2100 Bioanalyzer, Agilent Technologies
Inc., Santa Clara, CA, USA). Reverse transcription of total RNA
was carried out using IScript cDNA Synthesis Kit (Bio-Rad,
Hercules, CA, USA) according to the manufacturer's
recommendations. The relative expression levels of genes of
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interest (Lp-PLA2, biglycan and versican) were performed in
triplicate using QuantiTect Primer Assay and QuantiTect SYBR
Green PCR Kit (Qiagen, Hilden, Germany) on the MyiQ
Thermal Cycler (Bio-Rad, Hercules, CA, USA) as previously
described [28]. QuantiTect Hs-ACTB Assay (Qiagen, Hilden,
Germany) was used as normalizer.
Western Blotting
Western blotting analysis was performed as described
elsewhere [5,28]. The following primary antibodies against the
indicated proteins were used: Lp-PLA2 (ab 96619), versican
(ab19345), biglycan (ab 49701) (Abcam, Cambridge, UK), and
beta-actin (SC-130656) (Santa Cruz Biotechnology Inc., Santa
Cruz, CA, USA). As secondary antibodies, appropriate
horseradish peroxidase-conjugated antibodies were used and
the bands visualized according to a standard
chemiluminescence protocol (Immobilon Western, Millipore,
Billerica, MA, USA). Protein expression was quantified using
VersaDoc Imaging System (Bio-Rad, Hercules, CA, USA).
Statistical analysis
Data are expressed as mean±SD values if normally
distributed. Differences between two groups were analysed by
a two-tailed unpaired Student’s t-test. The relationship between
variables was assessed by linear regression. A probability
value (P) of 0.05 was considered to be statistically significant.
All data were analysed with StatView (SaS).
Results
In vivo study
Both groups of non-smokers and smokers were comparable
with respect to age and gender; moreover waist circumference,
body mass index, systolic and diastolic blood pressure, plasma
glucose and lipid profile were within normal range and similar in
both groups. In contrast, smokers compared to non-smokers,
had significantly higher levels of circulating oxLDL (44.7±9.1
versus 15.8±7.5 µg/ml respectively, P<0.001). Moreover our
results showed higher plasma levels of Lp-PLA2 (256.7±63.1
versus 191.3±48.0 ng/ml respectively, P<0.001) and of lysoPC
(133.8±39.4 µmol/l and 95.3±20.8 µmol/l respectively,
P<0.001) in smokers compared to non-smokers. These data
are presented in Table 1. We also found a significant positive
correlation between plasma concentrations of ox-LDL and of
LpPLA2 (r=0.654, P<0.001) and between plasma
concentrations of Lp-PLA2 and of lysoPC in the whole
population of subjects studied (r=0.639, P<0.001), (Figure 1, A-
B).
We then examined the expression of Lp-PLA2 in PBMC. As
shown in Figure 2, A-B, our results demonstrated a significantly
increased expression of Lp-PLA2 (mRNA and protein) in
smokers compared to non-smokers. These findings together
with the fact that in all subjects we found a positive correlation
between the expression of mRNA Lp-PLA2 in PBMC and the
plasma concentrations of Lp-PLA2 (r=0.484, P<0.001), (Figure
2C) indicate that in our subjects the expression of Lp-PLA2 in
PBMC may be a major source of circulating Lp-PLA2.
To evaluate cigarette smoking-induced early alterations of
the arterial wall, CIMT was measured in all the subjects. In
smokers mean and maximal CIMT, though in a normal range,
were significantly higher than in non-smokers; in particular,
mean CIMT was 0.65±0.09 mm in smokers and 0.54±0.06 mm
in non-smokers (P<0.001) and maximal CIMT was 0.73±0.10
mm in smokers and 0.63±0.06 in non-smokers (P<0.001), as
shown in Figure 3A. Interestingly, our results also showed a
positive correlation between mean CIMT and lysoPC (r=0.551,
P<0.001) in all the subjects (Figure 3B). Furthermore a
significant positive correlation was also demonstrated between
plasma oxLDL and mean CIMT (r=0.543, P<0.001) and
between Lp-PLA2 and mean CIMT (r=0.382, p<0.001) in all the
subjects. Finally, there was no evidence of carotid plaques in
any subject; this finding was not unexpected given their
relatively young age and the absence of other cardiovascular
risk factors.
In vitro study
OxLDL- and oxPAPC-induced Lp-PLA2 expression in
PBMC.  Next we tested the hypothesis that circulating oxLDL,
and in particular the oxPAPC contained in oxLDL, may have a
role in up-regulating the expression of Lp-PLA2 in PBMC. Our
results showed that oxLDL (at concentrations similar to those
found in smoker's serum) and oxPAPC induced a dose-
dependent increase (P<0.01 starting from 50 µg/ml) of Lp-
PLA2 (mRNA expression), whereas nLDL and lysoPC did not
(Figure 4 A-B). Moreover the mRNA expression of Lp-PLA2
induced by oxLDL was significantly higher than that induced by
oxPAPC (P<0.01).
Table 1. Clinical, metabolic and circulating inflammatory
and oxidative stress parameters of non-smokers and
smokers.
 Non-smokers Smokers P
 (n = 45) (n = 45)  
Age (years) 35.1±6.1 36.5±6.4 ns
Male/female 23/22 25/20 ns
BMI (Kg/m2) 23.1±2.2 22.4±2.8 ns
SBP (mmHg) 116.4±14.1 118.1±15.5 ns
DBP (mmHg) 72.1±12.7 71.3±11.2 ns
Heart rate (bpm) 65.6±8.3 73.2±7.8 ns
Waist circumference (cm) 79.0±11.9 76.5±10.8 ns
Total cholesterol (mg/dl) 189.7±24.6 186.4±21.3 ns
LDL cholesterol (mg/dl) 115.5±20.1 116.3±19.4 ns
HDL cholesterol (mg/dl) 52.5±11.4 51.4±10.9 ns
Triglycerides (mg/dl) 89.7±27.6 92.9±25.6 ns
Plasma glucose (mg/dl) 79.9±10.4 83.4±9.3 ns
oxLDL (µg/ml) 15.8±7.5 44.7±9.1 0.001
Lp-PLA2 (ng/ml) 191.3±48.0 256.7±63.1 0.001
lysoPC (µM) 95.3±20.8 133.8±39.4 0.001
Legend: BMI= body mass index; SBP= systolic blood pressure; DBP= diastolic
blood pressure; oxLDL= oxidized LDL; Lp-PLA2= lipoprotein associated-
phospholipase A2; lysoPC= lysophosphatidilcholine.
doi: 10.1371/journal.pone.0083092.t001
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Therefore, to clarify whether this up-regulation of mRNA Lp-
PLA2 could be due, at least in part, to the ability of oxLDL to
transfer and/or generate oxidized phospholipids on PBMC
membranes, we quantified the content of POVPC, PGPC and
of lysoPC after incubation of PBMC with nLDL or oxLDL. Our
results showed that oxLDL-treated PBMC contained more
oxPAPC (POVPC and PGPC) and lysoPC that nLDL-treated
PBMC. Figure 5 A-C shows a representative mass spectometry
analysis of POVPC, PGPC and of lysoPC content after
incubation of PBMC in presence of nLDL and oxLDL.
Figure 1.  Correlation between plasma lipoprotein-
associated phospholipase A2 (Lp-PLA2) and oxidized LDL
(oxLDL) and between plasma LpPLA2 and
lysophosphatidylcholine (lysoPC).  (A) Correlation between
plasma Lp-PLA2 and oxLDL and (B) correlation between
plasma Lp-PLA2 and lysoPC concentrations in the whole
population of subjects studied.
doi: 10.1371/journal.pone.0083092.g001
Figure 2.  Lipoprotein-associated phospholipase A2 (Lp-
PLA2) mRNA and protein expression in peripheral blood
mononuclear cells (PBMC) of non-smokers and smokers
and correlation between Lp-PLA2 expression in PBMC and
plasma Lp-PLA2.  (A) mRNA was analyzed by quantitative
Real-Time PCR. Normalized gene expression levels were
given as the ratio between the mean value for the Lp-PLA2
gene and that for beta-actin in each sample. Data are
presented as mean+SD. *P<0.001 versus non-smokers. (B)
Representative Western blot analysis for Lp-PLA2 and the
average quantification obtained by densitometric analysis of all
the samples (20 subjects per group, randomly selected). (C)
Correlation between Lp-PLA2 mRNA expression in PBMC and
plasma concentrations of Lp-PLA2 in the whole population of
subjects studied.
doi: 10.1371/journal.pone.0083092.g002
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Figure 3.  Carotid intima-media thickness (CIMT) in non-smokers and smokers and correlation between CIMT and plasma
concentrations of lysophosphatidylcholine (lysoPC).  (A) Mean and maximal CIMT values in non-smokers and smokers,
*P<0.001 versus non-smokers. Data are presented as mean+SD. (B) Correlation between CIMT and plasma concentrations of
lysoPC in the whole population of subjects studied.
doi: 10.1371/journal.pone.0083092.g003
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Figure 4.  Dose-response effect of native LDL (nLDL), oxidized LDL (oxLDL), oxidized phospholipids (oxPAPC), and of
lysophosphatidylcholine (lysoPC) on mRNA expression of Lp-PLA2.  (A) Dose-response effect of nLDL, oxLDL and oxPAPC
(0-100 µg/ml) and (B) dose-response effect of lysoPC (0-50 µM) on mRNA expression of Lp-PLA2 after incubation with PBMC for 6
h. Normalized gene expression levels were given as the ratio between the mean value for Lp-PLA2 gene and that for the beta-actin
in each sample. Data represent the mean±SD of measurements performed in triplicate in four different occasions. *P<0.01 versus
basal, †P<0.01 versus oxPAPC.
doi: 10.1371/journal.pone.0083092.g004
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Figure 5.  Representative mass spectrometry (MS) analysis of PBMC extract.  PBMC were incubated with native LDL (nLDL) or
oxidized LDL (oxLDL) (100 µg/ml) for 18 h. Indicated peaks correspond to A) lysoPC (496.1 m/z), B) POVPC (594.4 m/z) and C)
PGPC (610.4 m/z). MS analysis of PBMC extract (1/10 with 10 mM ammonium acetate in methanol) was performed on an ion trap
mass spectrometer where ions were generated with an electrospray ionization source at 350° C, and spectra were acquired in the
positive mode (total ion range 480–640 m/z).
doi: 10.1371/journal.pone.0083092.g005
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Effect of increasing concentrations of lysoPC on
biglycan and versican (mRNA and protein) expression in
human aortic SMCs.  Moreover, we exposed quiescent and
proliferating human aortic SMCs to increasing concentrations
of lysoPC and evaluated the expression of biglycan and
versican. As shown in Figure 6 A-B, our results indicated that
the expression of both biglycan and versican was significantly
higher in proliferating compared to quiescent human aortic
SMCs; however and more interestingly, both biglycan and
versican mRNA expression was dose-dependently increased in
human aortic SMCs incubated with lysoPC (P<0.01 starting
from 25 µmol/l). In parallel with mRNA, similar results were also
found for the protein expression of biglycan (Figure 7A-D) and
versican (data not shown).
Discussion
Oxidative stress induced by cigarette smoking plays a central
role in accelerated cardiovascular aging in smokers [4]. In this
study, we first showed higher levels of oxLDL in smokers
compared to non-smokers, confirming previous studies that
demonstrated an increase of oxidative stress markers in
smokers [4,5,34]. Even if augmented levels of Lp-PLA2 have
been observed in smokers [35,36], this is the first
demonstration of higher plasma levels of Lp-PLA2 and of
lysoPC in young healthy smokers compared with age- and sex-
matched non-smokers. Although it could be argued that in this
study we measured only Lp-PLA2 mass levels, there are
convincing epidemiological data showing that Lp-PLA2
concentrations can be assessed by either enzyme activity or
enzyme mass measurements [7]. Moreover, the fact that in
both groups the HDL and LDL cholesterol levels were normal
and comparable, allows us to reasonably exclude that Lp-PLA2
levels may depend on different lipoprotein carrier concentration
in plasma. On the contrary, the positive correlation between Lp-
PLA2 and oxLDL found in all the subjects, suggests that oxLDL
may influence plasma levels of Lp-PLA2. Furthermore our
results also showed a positive correlation between plasma Lp-
PLA2 and lysoPC, indicating that Lp-PLA2 may be a major
determinant of lysoPC plasma levels.
Several studies show that the activation of leukocytes plays
a crucial role in atherogenesis and that Lp-PLA2 is mainly
secreted by inflammatory cells in circulation or in the
atherosclerotic plaques [7]. In this study we also demonstrated
a positive correlation between mRNA expression of Lp-PLA2 in
PBMC and plasma Lp-PLA2 levels in all the subjects; this
finding is in line with a recent study showing that in non-obese
women plasma Lp-PLA2 activity positively correlated with
PBMC Lp-PLA2 activity [37]. Moreover, given the strong
association between carotid and coronary atherosclerosis
[12,13], the evidence that in no subject carotid plaques were
detected, supports the conclusion that PBMC are a major
source of Lp-PLA2 in our young healthy subjects.
Furthermore, another peculiarity of this study is the
increased expression (mRNA and protein) of Lp-PLA2 in
PBMC derived from smokers. Even though epidemiological
studies have demonstrated an association between cigarette
smoking and Lp-PLA2 activity [35,36], whether the oxidative
stress associated with cigarette smoking may have a causal
role is still not known. Since oxLDL contain different oxidized
phospholipids, some of which are thought to act as intracellular
signaling molecules [38], in this study we tested the hypothesis
that circulating oxLDL may up-regulate the mRNA expression
of Lp-PLA2 in PBMC. In particular the role of oxPAPC as
intracellular signaling molecules beside the function of
membrane phospholipid metabolites is becoming increasingly
clear [38]. In this context we have already demonstrated an
increased formation of oxPAPC in PBMC of smokers [5],
together with their potential to increase the expression of
inflammatory genes [5] and to decrease the expression of
antioxidant genes [5,6]. In this study we go further and
demonstrate that oxLDL and oxPAPC, but not nLDL, dose-
dependently increased mRNA expression of Lp-PLA2 in PBMC
from healthy donors. A likely explanation of this finding may be
that these major oxidized components of oxLDL are transferred
or induced on PBMC membranes. The evidence obtained by
mass spectrometry that the content of oxPAPC in PBMC was
significantly increased after exposure of oxLDL supports the
hypothesis that oxPAPC may have a causal role in up-
regulation of Lp-PLA2 mRNA expression in PBMC.
Moreover the fact that the concentrations of oxLDL
stimulating PBMC Lp-PLA2 expression in vitro were similar to
those found in smoker’s plasma supports the hypothesis that
plasma oxLDL may play an important role in up-regulating Lp-
PLA2 mRNA expression in PBMC of smokers. This finding,
albeit in different experimental conditions, is in line with a
recent paper showing that a synthesized oxidized phospholipid
was able to up-regulate Lp-PLA2 mRNA expression in THP-1
cells [10], and also with a porcine model of diabetes
demonstrating up-regulation of Lp-PLA2 mRNA expression by
PBMC in the presence of advanced glycation end products
[39]. As far as the possible mechanism by which oxLDL
induces Lp-PLA2 expression is concerned, it has been shown
that oxLDL and more specifically its oxidized phospholipids,
can up-regulate Lp-PLA2 expression in THP-1 cells through
activation of phosphatidylinositol 3-kinase and p38 mitogen-
activating protein kinase pathway [10].
A further result of this study is the demonstration of higher
CIMT values in healthy smokers than in age-sex matched non-
smokers.This finding is in accordance with epidemiological
studies that have consistently demonstrated, albeit in older
subjects, that cigarette smoking is associated with higher CIMT
[16,17]. Although convincing evidence has demonstrated a
relationship between Lp-PLA2 and incident cardiovascular
disease, the association between Lp-PLA2 and CIMT is less
clear [7] and probably not independent of other cardiovascular
risk factors [40,41]. LysoPC is considered one of the major
determinants of the atherosclerotic properties of oxLDL [8,11],
and it has been shown to induce several key steps in the
development of atherosclerosis [8,11]. Interestingly in this
study we demonstrated for the first time a positive correlation
between CIMT and plasma lysoPC in all the subjects. In this
context, recent data suggest that cigarette smoking has a
specific fibrogenic effect which causes intimal thickening, a
lesion composed of smooth muscle cells and proteoglycans/
collagen matrix with rare inflammatory cells [20-22]. The
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Figure 6.  Dose-response effect of lysophosphatidylcholine (lysoPC) on biglycan and versican mRNA expression.  Effect of
increasing concentrations (0-50 µM) of lysoPC on (A) biglycan and on (B) versican mRNA expression after incubation with
quiescent and proliferating human aortic SMCs for 24 h. Normalized gene expression levels were given as the ratio between the
mean value for target gene and that for the beta-actin in each sample. Data represent the mean±SD of measurements performed in
triplicate in four different occasions. * P<0.01 versus quiescent; †P<0.01 versus basal.
doi: 10.1371/journal.pone.0083092.g006
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proteoglycans and specifically biglycan and versican, that are
predominant vascular extracellular matrix proteoglycans, are
known to play a pivotal role in early atherogenesis [19]. In this
regard, recent observations have shown that the initial
entrapment of LDL within the extracellular matrix depends on
interaction of LDL with biglycan and versican [20-22] and
Figure 7.  Dose-response effect of lysophosphatidylcholine (lysoPC) on biglycan protein expression.  Effect of increasing
concentrations (0-50 µM) of lysoPC on biglycan protein expression after incubation with (A) quiescent and (C) proliferating human
aortic SMCs for 24 h. Data are the average quantification obtained by densitometric analysis of all the samples, expressed as the
density ratio of target to control (beta-actin) in arbitrary units x10. Figure also shows a representative Western blot analysis (B and
D) of three independent experiments for biglycan.
doi: 10.1371/journal.pone.0083092.g007
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atherosclerosis-prone arteries, such as the coronary artery,
have a thickened intima enriched in versican and biglycan
[20-22]. Therefore to better understand the possible causal role
of lysoPC in the higher CIMT found in smokers, we performed
an in vitro study aimed to assess whether lysoPC may
influence proteoglycans synthesis. Our results support this
hypothesis. In fact we demonstrated both an increased
expression of biglycan and versican in proliferating compared
to quiescent human aortic SMCs and a lysoPC dose-
dependent increase in the expression of biglycan and versican
in human aortic SMCs. Our results, though in different
experimental conditions, are in agreement with previous data
showing that lysoPC was able to increase proteoglycans
synthesis in SMCs [24].
In conclusion, in our otherwise healthy smokers a further
effect of raised oxidative stress is up-regulation of Lp-PLA2
expression in PBMC with subsequent increase of plasma Lp-
PLA2 and lysoPC. Moreover the correlation between lysoPC
and CIMT together with the finding that lysoPC up-regulates
proteoglycan synthesis suggests that lysoPC may be a link
between smoking and intimal thickening.
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